Paper17538161
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Vermorken JB and 9 others. J Clin Oncol, 2007. Cited by 803 papers, by iCite.
Cite this record
ConductScience Library. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. Papers, record 17538161. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538161
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antineoplastic Agents | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| ErbB Receptors | Major topic |
| Head and Neck Neoplasms | Major topic |
| Adult | |
| Aged | |
| Antibodies, Monoclonal, Humanized | |
| Cetuximab | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Organoplatinum Compounds | |
| Prognosis |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02014831 | Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) | Background | ClinicalTrials.gov | |
| NCT03356223 | Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 | Background | ClinicalTrials.gov | |
| NCT06332092 | FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma | Background | ClinicalTrials.gov |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 17538157 | Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. | https://conductscience.org/library/papers/17538157 | PubMed |
| Comment in | 17909551 | Is cetuximab active in patients with cisplatin-refractory squamous cell carcinoma of the head and neck? | https://conductscience.org/library/papers/17909551 | PubMed |
Cited by421
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 803 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42868984 | A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent/metastatic head and neck squamous-cell carcinomas. | ESMO Open | 2026 | https://conductscience.org/library/papers/42868984 | PubMed |
| 42706605 | Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. | Cancer Med | 2026 | https://conductscience.org/library/papers/42706605 | PubMed |
| 42691952 | Window-of-Opportunity Study Utilizing Preoperative Cetuximab in Patients with Head and Neck Cancer. | Cancer Res Commun | 2026 | https://conductscience.org/library/papers/42691952 | PubMed |
| 42668534 | Efficacy and safety of SCT200 in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum failure: A phase 2 study. | Cancer Pathog Ther | 2026 | https://conductscience.org/library/papers/42668534 | PubMed |
| 42635798 | Ras homolog family member A expression is associated with reduced cetuximab sensitivity in head and neck squamous cell carcinoma. | J Int Med Res | 2026 | https://conductscience.org/library/papers/42635798 | PubMed |
| 42581129 | Adverse events of cetuximab sarotalocan in photoimmunotherapy: insights from the Japanese adverse drug event report database. | Cancer Chemother Pharmacol | 2026 | https://conductscience.org/library/papers/42581129 | PubMed |
| 42352422 | Spatial Biomarker Deep Learning Model Predicts Response to PI3K Inhibition in Head and Neck Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42352422 | PubMed |
| 42260304 | Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 study. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42260304 | PubMed |
| 42218660 | Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study. | J Clin Oncol | 2026 | https://conductscience.org/library/papers/42218660 | PubMed |
| 41948974 | Molecular and Cell Biological Characterization of Patient-Derived Head and Neck Squamous Carcinoma Cell Lines. | Cancer Sci | 2026 | https://conductscience.org/library/papers/41948974 | PubMed |
| 41777651 | Characterization of skin adverse events associated with cetuximab: real-world insights from the two global pharmacovigilance databases of FAERS and VigiAccess. | Front Oncol | 2026 | https://conductscience.org/library/papers/41777651 | PubMed |
| 41690455 | Inhibition of α-1,3-mannosyltransferase sensitizes head and neck squamous cell carcinomas to cetuximab via endoplasmic reticulum stress. | Cell Stress Chaperones | 2026 | https://conductscience.org/library/papers/41690455 | PubMed |
| 41605945 | Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial. | Nat Commun | 2026 | https://conductscience.org/library/papers/41605945 | PubMed |
| 41584602 | Sequential salvage systemic therapy after immunotherapy in head and neck cancer: a real-world study. | Front Oncol | 2025 | https://conductscience.org/library/papers/41584602 | PubMed |
| 41465166 | Current and Emerging Protein Biomarkers for the Diagnosis and Prognosis of Head and Neck Cancer. | Genes (Basel) | 2025 | https://conductscience.org/library/papers/41465166 | PubMed |
| 41426177 | Successful Treatment of Recurrent Unresectable Oral Cancer with Sequential Targeted Therapy, Surgery, and Metronomic Chemotherapy. | South Asian J Cancer | 2025 | https://conductscience.org/library/papers/41426177 | PubMed |
| 41375018 | Emerging and Investigational Systemic Therapies in Recurrent/Metastatic Head and Neck Cancer After Progression on Immunotherapy. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41375018 | PubMed |
| 41344992 | TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/41344992 | PubMed |
| 41291854 | Development of a bispecific antibody that inhibits EGFR and B7H3 in NSCLC. | Biomark Res | 2025 | https://conductscience.org/library/papers/41291854 | PubMed |
| 41117857 | Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41117857 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17538161
GET https://conductscience.org/api/papers/v1/17538161/cited_by?page=2